Clinical Trial Update: Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing docetaxel alone versus docetaxel plus estramustine in men with hormone-refractory (castration-resistant) metastatic prostate cancer to…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Estramustine (estramustine)

Snippet

Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Conditions: Hormone Resistant Prostate Cancer, Metastatic Prostate Cancer | Phase 2 | Status: COMPLETED